UPDATE: To Watch the Replay of Kyle’s Option Rocket Webinar
>>> Click Here and Register <<<
You’ll receive your replay link in a few minutes.
Big Alert: I’m having an exclusive webinar on May 24th at 8 PM Eastern. I’ll be releasing a new option strategy I’m calling I.G.N.I.T.E. I’ll also be showing how you can use a simple option strategy to hit huge percentage returns in all types of stocks.
I already have thousands of people attending and our servers can only hold so many, so be sure to secure your seat right now!
Exciting day out there. What a great move so far on PTIE! I’m up about $4,500 on the position so far and I think shares are going to continue higher. Couldn’t be happier!
—– Related —–
FREE DOWNLOAD
Kyle Dennis FREE EBOOK “The $2.9 Million Biotech Trader Playbook”
This book has helped thousands of other traders learn the basics of biotech, and how to easily spot winning trades.
Whether you are new trader or a 30-year veteran, this book will help you find stocks that are primed to make parabolic moves. These strategies are Kyle’s secret weapons that have help him net over $3 Million in profits…and they are all yours for free.
This is normally $97.00, but it’s yours FREE!
I also added BLPH to the portfolio, which should have some news coming out within the next 6-8 weeks.
A bunch of the ASCO abstracts were released and we should have a really active day tomorrow.
I’m going to leave a bunch of the ASCO names we were watching on the list still here today to see where things shape up. Maybe a dip provides an opportunity to buy, or some good news in the morning will cause a further rally.
So far, it looks like LOXO is the big winner and JNCE is the big loser. Besides that not too much looks that exciting in the abstracts – maybe more to come at the actual conference in early June.
I’ll be taking off May 17th FDA Insider Watch List and RCKT here, as both have data upcoming soon and had fantastic catalyst runs! I’m also taking offDERM, which I think is pretty near fully valued before their FDA approval date.
In the meantime, a few more new names to add to the watch list are AQXP, DRRX, and BLPH.
Just a reminder, charts and targets are updated every Monday morning!
New Catalyst Swing names (1 – 4 week holds) I am watching…
Aquinox Pharmaceuticals (AQXP)
Catalyst Dates: Phase 3 data due out in the third quarter
Buy Zone: $1.30 to $1.45
Profit Zone: $1.80 or higher
Stop Zone: $1.20 or below
Bellerophon Therapeutics (BLPH)
Catalyst Dates: Interim Phase 3 data release in the middle of 2018 (likely late June or July)
Buy Zone: $2.20 to $2.40
Profit Zone: $2.75 or higher
Stop Zone: $2.10 or below
Durect Corporation (DRRX)
Catalyst Dates: Advisory Committee meeting on June 26th, FDA Approval dates on July 28th and August 7th
Buy Zone: $1.75 to $2.00
Profit Zone: $2.40 or higher
Stop Zone: $1.65 or below
Catalyst Swing names (1 – 4 week holds) I am watching…
Array BioPharma (ARRY)
Catalyst Dates: Phase 3 data due out June 20-23. FDA approval date of June 30 as well.
Buy Zone: $14.50 to $15.50
Profit Zone: $18.00 or higher
Stop Zone: $14.00 or below
Global Blood Therapeutics (GBT)
Catalyst Dates: Phase 3 data likely due out in June. Officially in the “first half”
Buy Zone: $48.00 to $50.00
Profit Zone: $57.00 or higher
Stop Zone: $45.00 or below
Pluristem Therapeutics (PSTI)
Catalyst Dates: Phase 2 data due out to be published in June.
Buy Zone: $1.30 to $1.45
Profit Zone: $1.80 or higher
Stop Zone: $1.20 or below
Marinus Pharmaceuticals (MRNS)
Catalyst Dates: Phase 2 data due out in the third quarter. Two other Phase 2 datas due out in the fourth quarter.
Buy Zone: $4.25 to $4.75
Profit Zone: $6.00 or higher
Stop Zone: $4.00 or below
GTx, Inc (GTXI)
Catalyst Dates: Updated date to be presented May 18 at the AUA Meeting
Buy Zone: $16.50 to $17.50
Profit Zone: $19.00 or higher
Stop Zone: $16.00 or below
Cytokinetics Incorporated (CYTK)
Catalyst Dates: Phase 2 data due out June 16
Buy Zone: $8.50 to $9.00
Profit Zone: $10.00 or higher
Stop Zone: $7.40 or below
Zogenix (ZGNX)
Catalyst Dates: Phase 3 data due late second quarter (likely June)
Buy Zone: $39.50 to $40.50
Profit Zone: $45.00 or higher
Stop Zone: $37.50 or below
Catalyst Biosciences (CBIO)
Catalyst Dates: Phase 2 data in July
Buy Zone: $26.50 to $28.50
Profit Zone: $33.00 or higher
Stop Zone: $25.00 or below
Pain Therapeutics (PTIE)
Catalyst Dates: Advisory Committee Meeting June 26th and FDA approval date of August 7th
Buy Zone: $7.50 to $8.25
Profit Zone: $9.50 or higher
Stop Zone: $7.00 or below
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.